The out-of-pocket expenditures needed to buy the equipment used in every practice have always been reduced or helped by our tax laws. Today, thanks to the new Jobs and Growth Tax Relief Reconciliation Act of 2003, the needed equipment may be more affordable than ever.
Jonathan E. Rosenberg, MD, discusses the FDA approval of perioperative durvalumab plus enfortumab vedotin and considerations for treatment selection in cisplatin-ineligible MIBC.
Jessica Feehan, NP-C, discusses the expanding role of APPs in urology, from clinical leadership and procedures to care coordination and treatment initiation.
Sam S. Chang, MD, MBA, discusses treatment selection after BCG failure, including bladder-sparing options, cystectomy considerations, and the need for sequencing data.